COVID-19 Member Resources | HealthEquity Skip to content

Covid-19 | Member Resources

Regulatory Updates

Read the latest information to see how rule changes could impact your benefits.

*We encourage you bookmark this page for future reference.

See our response for employers

Latest Update

February 2, 2023

End of COVID National Emergency

On January 30, 2023, the White House announced that it plans to end the COVID-19 National Emergency and public health emergency declarations on May 11, 2023. With this announcement, the 60-day period following the end of the national emergency is expected to begin on May 12, 2023, thus counting down the end of the COVID-19 Outbreak Period and certain ERISA health and welfare plan benefit deadlines that have been extended during this period will resume beginning July 11, 2023.

During the week of March 6, 2023, our teams will begin work to update reimbursement account (RA) plan run-out dates for impacted plans. This means that your “claim it by” date may be changing for certain plan years and claims must be submitted by a new date based on your specific plan details. You can expect additional communication from your employer in the coming weeks. Please pay special attention to your ‘claim it by’ and claims submission dates in your member portal.

March 26, 2021

Recently, the IRS announced that Personal Protective Equipment (PPE) used primarily for the purpose of preventing the spread of Novel Coronavirus Disease 2019 (COVID-19) is now a qualified medical expense eligible for reimbursement under Healthcare Flexible Spending Accounts (HCFSAs) Archer medical savings accounts (Archer MSAs), health reimbursement arrangements (HRAs), and Health Savings Accounts (HSAs). This includes face masks, hand sanitizer and sanitizing wipes.

Read more

Frequently Asked Questions

There have been a lot of changes during this past year as the nation deals with COVID-19. This list will hopefully help you find the answers you need regarding your health accounts and the recent changes.

Have more questions? Contact us.